2017
DOI: 10.1016/j.ultrasmedbio.2016.11.001
|View full text |Cite
|
Sign up to set email alerts
|

Cesarean Scar Pregnancy: Comparing the Efficacy and Tolerability of Treatment with High-Intensity Focused Ultrasound and Uterine Artery Embolization

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
30
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(33 citation statements)
references
References 26 publications
3
30
0
Order By: Relevance
“…No additional treatment was necessary. During follow-up, serum b-hCGof all the patients in the three groups returned to normal levels in $30 days, which was similar to previous reports [13,14,19]. Although uterine perforation at a previous caesarean scar during D&C procedure has been reported in other studies [14], this complication didn't occur in our study.…”
Section: Discussionsupporting
confidence: 91%
See 1 more Smart Citation
“…No additional treatment was necessary. During follow-up, serum b-hCGof all the patients in the three groups returned to normal levels in $30 days, which was similar to previous reports [13,14,19]. Although uterine perforation at a previous caesarean scar during D&C procedure has been reported in other studies [14], this complication didn't occur in our study.…”
Section: Discussionsupporting
confidence: 91%
“…A study in 2017 hypothesized that having a menolipsis time longer than 51 days and a gestational sac larger than 27 mm were risk factors for CSP patients with intraoperative hemorrhage [18]. Furthermore, in another study there was no serious adverse effects found, including heavy hemorrhaging, in which the HIFU treatment group had a small average gestational sac/mass diameter of 25.03 ± 8.75 mm [19].…”
Section: Discussionmentioning
confidence: 99%
“…The failure of treatment was defined as complications such as vaginal bleeding of more than 200 ml, a decrease in the serum β-hCG level by ≤50% for the seventh day, or treated by second line therapy such as Foley balloon catheter insertion, laparoscopy, or laparotomy (Xiao et al, 2017).…”
Section: Treatment Assessment and Follow-upmentioning
confidence: 99%
“…The main application areas of HIFU are the treatment of soft tissue tumors [5], [6] in liver [7], kidney [8], prostate [9], [10], breast [11], and in the brain [12], [13]. HIFU is not limited to the treatment of soft tissue tumors, and exploration of new avenues such as triggered drug delivery [14], treatment of bone tumors [15], neurological disorders [16], ectopic implantation [17], and pain management [18], [19] continues.…”
Section: Introductionmentioning
confidence: 99%